ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

JAGX vs MRK // 10Y YIELD & FRED MACRO BETA

Jaguar Health Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: JAGX 0 — MRK 9
■ METRIC PARITY
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAGX VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC JAGX MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 67.20% 74.80% -7.60 MRK /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.42% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin -0.50% 28.10% -28.60 MRK /net-margins <GO>
Revenue Growth (YoY) -1.50% 1.30% -2.80 MRK /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 7/9 -6.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.6 51.7 -10.10 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $15.9M $361.02B -$361.01B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR JAGX REV MRK REV JAGX GROSS % MRK GROSS % JAGX FCF MRK FCF
FY 2025 $11.5M $65.01B 67.2% 74.8% -$23.7M $12.36B
FY 2024 $11.7M $64.17B 83.3% 76.3% -$29.4M $18.10B
FY 2023 $9.8M $60.12B — — -$33.2M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAGX // BETA —
MRK // BETA 0.92